RAS-Targeting Drugs for Precision Oncology Market Size, Share & Trends Analysis Distribution by Drug Type (Small Molecule Inhibitors, Biologics, RNA-Based Therapies, Combination Therapies), Target Mutation (KRAS G12C, KRAS G12D, KRAS G12V, G12R, G12S, G12A, HRAS and NRAS, Pan-RAS), Indication (Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Other Cancers (e.g., HNSCC, melanoma, hematologic)), Route of Administration (Oral, Intravenous, Other Routes) and Segment Forecasts, 2025-2034

Explore our pricing plans

Single User License

$4456
  • PDF Report and Excel Datasheet
  • Delivered in 24-72 hrs. of purchase
  • Access for one individual only
  • Analyst support up to 3 Months
Purchase Now

Multi-User License

$7786
  • PDF Report, Excel Datasheet and Power BI
  • Delivered in 24-72 hrs. of purchase
  • Access for 5-6 individuals only
  • Analyst support up to 3 Months
Purchase Now

Corporate License

$10000
  • PDF Report, Excel Datasheet and Power BI
  • Delivered in 24-72 hrs. of purchase
  • Unlimited access for all employees within the organization
  • Analyst support up to 6 Months
Purchase Now

Quantitative Data Access

$1200
  • PowerBI/Excel Pivot Dashboard
  • Excel Datasheet and Power BI
  • Delivered in 24-72 hrs. of purchase
  • Unlimited access for all employees within the organization
  • Analyst support up to 6 Months
Purchase Now